<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Vanda Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc</link>
<description>Latest news and press releases for Vanda Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 21:13:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/vanda-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d36d78dffbe2df1208e8.webp</url>
<title>Vanda Pharmaceuticals Inc</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc</link>
</image>
<item>
<title>Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-appoints-dr-charles-duncan-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-appoints-dr-charles-duncan-to-its-board-of-directors</guid>
<pubDate>Wed, 22 Apr 2026 21:13:00 GMT</pubDate>
<description>Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22, 2026. Following Dr. Duncan's appointment, Vanda's Board of Directors is now comprised of seven directors, six of whom are independent.</description>
</item>
<item>
<title>Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-calls-on-fda-to-withdraw-proposal-from-fy-2027-legislative-agenda-that-would-extend-drug-review-timelines</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-calls-on-fda-to-withdraw-proposal-from-fy-2027-legislative-agenda-that-would-extend-drug-review-timelines</guid>
<pubDate>Thu, 09 Apr 2026 15:02:00 GMT</pubDate>
<description>Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget Justification.</description>
</item>
<item>
<title>Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-initiation-of-the-thetis-study-a-clinical-trial-of-nereustm-for-the-prevention-of-vomiting-induced-by-glp-1-receptor-agonists</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-initiation-of-the-thetis-study-a-clinical-trial-of-nereustm-for-the-prevention-of-vomiting-induced-by-glp-1-receptor-agonists</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>WASHINGTON, April 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of Thetis, a clinical trial</description>
</item>
<item>
<title>Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-calls-for-stronger-fda-action-to-accelerate-shift-from-animal-testing-to-human-relevant-methods</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-calls-for-stronger-fda-action-to-accelerate-shift-from-animal-testing-to-human-relevant-methods</guid>
<pubDate>Thu, 19 Mar 2026 20:34:00 GMT</pubDate>
<description>Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing, today voiced serious concerns over the U.S. Food and Drug Administration (FDA)'s new draft guidance, "General Considerations for the Use of New Approach Methodologies in Drug Development," released March 18, 2026, by the Center for Drug Evaluation and Research (CDER).</description>
</item>
<item>
<title>Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-announces-fda-grants-landmark-hearing-for-hetliozr-in-jet-lag-disorder-the-first-drug-approval-hearing-in-over-40-years</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-announces-fda-grants-landmark-hearing-for-hetliozr-in-jet-lag-disorder-the-first-drug-approval-hearing-in-over-40-years</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>WASHINGTON, March 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA)</description>
</item>
<item>
<title>Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-participation-in-the-2026-citizens-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-participation-in-the-2026-citizens-life-sciences-conference</guid>
<pubDate>Thu, 26 Feb 2026 21:35:00 GMT</pubDate>
<description>Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026. A corporate presentation is scheduled for 2:15 p.m. Eastern Time.</description>
</item>
<item>
<title>Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-filing-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-filing-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis</guid>
<pubDate>Wed, 25 Feb 2026 12:18:00 GMT</pubDate>
<description>Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), with a target action date of December 12, 2026.</description>
</item>
<item>
<title>Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-fda-approval-of-bysantitm-milsaperidone-for-the-treatment-of-bipolar-i-disorder-and-schizophrenia-a-new-chemical-entity-opening-new-horizons-in-psychiatric-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-fda-approval-of-bysantitm-milsaperidone-for-the-treatment-of-bipolar-i-disorder-and-schizophrenia-a-new-chemical-entity-opening-new-horizons-in-psychiatric-innovation</guid>
<pubDate>Fri, 20 Feb 2026 05:00:00 GMT</pubDate>
<description>WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has</description>
</item>
<item>
<title>Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-reports-fourth-quarter-210100444</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-reports-fourth-quarter-210100444</guid>
<pubDate>Wed, 11 Feb 2026 21:01:00 GMT</pubDate>
<description>Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announce-fourth-quarter-230100495</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announce-fourth-quarter-230100495</guid>
<pubDate>Wed, 04 Feb 2026 23:01:00 GMT</pubDate>
<description>Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026, after the market closes.</description>
</item>
<item>
<title>Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-receipt-fda-decision-letter-hetliozr-supplemental-new</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-receipt-fda-decision-letter-hetliozr-supplemental-new</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received a decision letter from the</description>
</item>
<item>
<title>Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-fda-approval-nereustm-tradipitant-prevention-vomiting</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-fda-approval-nereustm-tradipitant-prevention-vomiting</guid>
<pubDate>Tue, 30 Dec 2025 05:00:00 GMT</pubDate>
<description>WASHINGTON, Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA)</description>
</item>
<item>
<title>Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-announces-submission-biologics-license-application-fda-imsidolimab-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-announces-submission-biologics-license-application-fda-imsidolimab-treatment</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>WASHINGTON, Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application</description>
</item>
<item>
<title>Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-participation-jp-morgan-healthcare-conference-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-participation-jp-morgan-healthcare-conference-2025-12</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>WASHINGTON, Dec. 11, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P.</description>
</item>
<item>
<title>FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/fda-lifts-partial-clinical-hold-tradipitant-motion-sickness-2025-12-04</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/fda-lifts-partial-clinical-hold-tradipitant-motion-sickness-2025-12-04</guid>
<pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
<description>WASHINGTON, Dec. 4, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted</description>
</item>
<item>
<title>Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-provides-regulatory-update-tradipitant-motion-sickness-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-provides-regulatory-update-tradipitant-motion-sickness-2025-11</guid>
<pubDate>Fri, 28 Nov 2025 05:00:00 GMT</pubDate>
<description>FDA requests, and Vanda agrees to, a brief extension (to December 5, 2025) for the expedited re-review of the partial clinical hold on long-term</description>
</item>
<item>
<title>Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-reports-positive-results-tradipitant-preventing-glp-1-induced</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-reports-positive-results-tradipitant-preventing-glp-1-induced</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- Vanda</description>
</item>
<item>
<title>Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-participation-stifel-2025-healthcare-conference-2025</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announces-participation-stifel-2025-healthcare-conference-2025</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>WASHINGTON, Nov. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Stifel</description>
</item>
<item>
<title>Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-reports-third-quarter-2025-financial-results-2025-10-29</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-reports-third-quarter-2025-financial-results-2025-10-29</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>Fanapt® Q3 2025 net product sales increased by 31% to $31.2 million compared to Q3 2024 BysantiTM (milsaperidone) NDA for bipolar I disorder and</description>
</item>
<item>
<title>Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025</title>
<link>https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announce-third-quarter-2025-financial-results-october-29-2025</link>
<guid isPermaLink="true">https://6ix.com/company/vanda-pharmaceuticals-inc/news/vanda-pharmaceuticals-announce-third-quarter-2025-financial-results-october-29-2025</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>Conference Call and Webcast to Follow WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will</description>
</item>
</channel>
</rss>